Community feedback
Dr. Marko Kallio, University of Turku, Finland:
“This program is a fantastic opportunity to forward pre-clinical target discovery and validation. It can serve as an important bridge funding or allow execution of a few critical assays.”
Prof. Tea Lanisnik Rizner, University of Ljubljana, Slovenia:
“The major two advantages of the G4T program are: a short time needed for the application; and a fast response period – as applicants we have been informed about our proposals in less than three months.”
Prof. Gerd Multhaup, Free University of Berlin, Germany:
“We have experienced an excellent support by Bayer HealthCares scientists and have had encouraging discussions.”
Prof. Jean Y.J. Wang, Moores UCSD Cancer Center, La Jolla, USA:
“There are two advantages in the program. The first being the speed with which the grant is funded. The second being the potential of further collaboration in the future to advance the common research interests between my laboratory and Bayer AG.”
“This program is a fantastic opportunity to forward pre-clinical target discovery and validation. It can serve as an important bridge funding or allow execution of a few critical assays.”
Prof. Tea Lanisnik Rizner, University of Ljubljana, Slovenia:
“The major two advantages of the G4T program are: a short time needed for the application; and a fast response period – as applicants we have been informed about our proposals in less than three months.”
Prof. Gerd Multhaup, Free University of Berlin, Germany:
“We have experienced an excellent support by Bayer HealthCares scientists and have had encouraging discussions.”
Prof. Jean Y.J. Wang, Moores UCSD Cancer Center, La Jolla, USA:
“There are two advantages in the program. The first being the speed with which the grant is funded. The second being the potential of further collaboration in the future to advance the common research interests between my laboratory and Bayer AG.”